XBIT

XBiotech Inc. is a biopharmaceutical company focused on discovering and developing True Human monoclonal antibodies for treating a variety of diseases. The company's lead product candidate, bermekimab, is a therapeutic antibody targeting interleukin-1 alpha, being developed for inflammatory conditions including hidradenitis suppurativa and other dermatological diseases. XBiotech utilizes its proprietary True Human antibody discovery platform to develop treatments with potentially reduced immunogenicity.